Print

Purpose

This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Confirmed diagnosis of COVID-19 - Personal history of either - Chronic hepatitis C - Chronic hepatitis B - Alcoholic liver disease - Non alcoholic liver disease - Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis - Cryptogenic cirrhosis - Hepatocellular carcinoma

Exclusion Criteria

  • Non-COVID-19 patient

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Chronic Liver Disease Group COVID-19 patients with Chronic Liver Disease.
  • Other: Prospective Chart Review
    Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.
Control Group COVID-19 patients without Chronic Liver Disease.
  • Other: Prospective Chart Review
    Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.

Recruiting Locations

More Details

NCT ID
NCT04439084
Status
Completed
Sponsor
Stanford University

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.